<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042302</url>
  </required_header>
  <id_info>
    <org_study_id>TQD LUNG 001</org_study_id>
    <nct_id>NCT00042302</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>QLT Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QLT Inc.</source>
  <brief_summary>
    <textblock>
      To determine whether tariquidar + combined first-line chemotherapy of paclitaxel/carboplatin&#xD;
      in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly&#xD;
      improve overall survival compared with placebo + paclitaxel/carboplatin. To compare the&#xD;
      effects of tariquidar/paclitaxel/carboplatin with placebo/paclitaxel/carboplatin on tumor&#xD;
      response, time to disease progression, performance status, symptom progression, and quality&#xD;
      of life in patients with Stage IIIb/IV NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>540</enrollment>
  <condition>Stage IIIb Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tariquidar + paclitaxel/carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo + paclitaxel/carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have histologically or cytologically proven NSCLC, stage IIIb or stage&#xD;
             IV, requiring first-line chemotherapy.&#xD;
&#xD;
          2. Patients who have a WHO performance status of 1 or 0 and life expectancy of greater&#xD;
             than 3 months.&#xD;
&#xD;
          3. Patients who are 18 years of age or older and age of consent.&#xD;
&#xD;
          4. Patients who are women of child-bearing potential must not be pregnant or lactating,&#xD;
             must have a negative pregnancy test (serum or urine) at screening, and must be&#xD;
             practicing an adequate method of birth control.&#xD;
&#xD;
          5. Patients who have neutrophils greater or equal to 1.5 x 103/µL; platelets greater or&#xD;
             equal to 100 x 103/µL; bilirubin less or equal to 1.5 times the upper limit of normal&#xD;
             or less or equal to 26 µmol/L (1.5 mg/dL); transaminases less or equal to 2.5 times&#xD;
             the upper limit of normal or, for patients with known liver metastases, less or equal&#xD;
             to 5 times the upper limit of normal; and creatinine less or equal to 141 µmol/L (1.6&#xD;
             mg/dL) or calculated creatinine clearance greater or equal to 60 mL/min prior to study&#xD;
             treatment.&#xD;
&#xD;
          6. Patients who are able to give written informed consent and comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are eligible for radiotherapy or surgery for curative intent.&#xD;
&#xD;
          2. Patients who have had previous chemotherapy for NSCLC.&#xD;
&#xD;
          3. Patients who have a WHO performance status greater than 1.&#xD;
&#xD;
          4. Patients with bronchoalveolar carcinoma (an adenocarcinoma in which cylindrical tumor&#xD;
             cells grow upon the walls of pre-existing alveoli, from WHO histological typing of&#xD;
             lung tumors [1]).&#xD;
&#xD;
          5. Patients who have previous or current primary malignancies at other sites within the&#xD;
             last 5 years, with the exception of adequately treated cone-biopsied carcinoma of the&#xD;
             cervix and basal or squamous cell skin carcinoma.&#xD;
&#xD;
          6. Patients who are a poor medical risk because of other nonmalignant systemic diseases&#xD;
             or active uncontrolled infections.&#xD;
&#xD;
          7. Patients who have symptomatic brain metastases.&#xD;
&#xD;
          8. Patients who have peripheral neuropathy of CTC grade 2, 3, or 4.&#xD;
&#xD;
          9. Patients who have other medical or surgical conditions that would contraindicate&#xD;
             chemotherapy.&#xD;
&#xD;
         10. Patients who have received experimental therapies within the last 4 weeks.&#xD;
&#xD;
         11. Patients who have known hypervitaminosis or known sensitivity to ascorbic acid,&#xD;
             vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, d-panthenol, or&#xD;
             vitamin E.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>July 26, 2002</study_first_submitted>
  <study_first_submitted_qc>July 31, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2002</study_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

